Who is sponsoring NCT03515824?

NCT03515824 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT03515824 study?

NCT03515824 studies Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms.

What is the status of NCT03515824?

NCT03515824 is currently TERMINATED.

Last reviewed 2021-03-09 · How we verify

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

NCT03515824 PHASE1 TERMINATED Results posted

The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort expansion to determine preliminary efficacy in participants with colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC) (Part B). No formal hypothesis testing will be done in this study.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE1
Status	TERMINATED
Enrolment	22
Start date	Mon Aug 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neoplasms
Colorectal Neoplasms
Head and Neck Neoplasms

Interventions

MK-1697

Countries

Hong Kong, Australia